Compare XYF & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | EMBC |
|---|---|---|
| Founded | 2014 | 1924 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.7M | 200.5M |
| IPO Year | 2018 | 2021 |
| Metric | XYF | EMBC |
|---|---|---|
| Price | $4.85 | $3.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 120.6K | ★ 2.1M |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.34% | 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.90 | $4.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $2.77 |
| 52 Week High | $20.36 | $15.55 |
| Indicator | XYF | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 27.72 |
| Support Level | $4.48 | $3.02 |
| Resistance Level | $5.11 | $3.48 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 23.19 | 17.31 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.